Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: Platter who wrote (72)	3/10/1998 1:05:00 PM
From: GuyNixon	Read Replies (2) \| Respond to of 410

J.P. Morgan medical technology analyst Michael Weinstein said he raised his first-quarter earnings estimate for Arterial Vascular Engineering Inc to $0.45 per share from $0.35 per share. Shares in the medical device maker were up 3-5/16 to 43-1/8 in heavy over-the-counter trading early Tuesday. Weinstein said the market for stents -- wire-mesh tubes used to support the insides of diseased blood vessels -- is surging. "The market in the first quarter has risen to $285 million in size, up from $260 million in the fourth and $175 million just six months ago," Weinstein said. Arterial began marketing its Micro Stent II in December and has already taken a 30-percent market share, he said. Guidant Corp <GDT.N>, another major stent maker, has retained a 53-percent share of the market, down from 72 percent in the quarter before, he said. "We expect AVE to win additional share in the months ahead with the upcoming launch of the GFX at the American College of Cardiology later this month, but for its share to peak much like Guidant's did with the entry of another player, Boston Scientific Corp <BSX.N> in June," Weinstein said. He added that Arterial seems to be busy on the acquisition front and faces the challenge of securing future growth.